Pharmacyte Biotech Inc (OTCMKTS:PMCB) reported that Chardan Capital Markets LLC, a global investment bank specializing in small, mid-cap and micro firms, issued an Industry Update on the company. Kenneth L. Waggoner, the CEO said that they are very delighted with Chardan’s industry update on company’s initiatives in the field. As stated in the report, the company expects it three clinical studies involving pancreatic cancer to be fully underway during 1Q2016.
These three studies consist of a Phase IIb clinical study in Australia in which Pharmacyte’s pancreatic cancer treatment will be analyzed to the current standard treatment of pancreatic cancer. Pharmacyte intends to commence the clinical studies by 4Q2015 and possibly sooner. The commencement date for the three clinical studies will depend upon regulatory acceptance of cGMP encapsulation facility in Thailand.
Nutra Pharma Corp. (OTCMKTS:NPHC) Submits Form 10-Q
Nutra Pharma Corp. (OTCMKTS:NPHC) submitted Form 10-Q wherein it revealed that net sales for 1H2015 came at $199,061 compared to $153,658 in the same period, a year earlier. This increase in sales can be attributed to an overall jump in sales of Nyloxin. The cost of sales came at $44,675 compared to $24,967 in 1H2014.
Nutra reported that total cost of sales covered the direct costs related with Nyloxin manufacturing. The gross profit margin in 1H2015 came at 77.6% compared to 83.8% for the first two quarters ended June 30, 2014. The decline in profit margin was a result of jump in the credit card processing fees.
Reliv International, Inc (NASDAQ:RELV) 2Q2015 Revenue Declines 14% YOY
Reliv International, Inc (NASDAQ:RELV) reported that revenue in 2Q2015 declined 14% YOY to $12.4 million from 2Q2014. The net sales in U.S. came at $9.6 million compared to $10.8 million in 2Q2014. Reliv reported net loss of $846,000 in 2Q2015 compared to $289,000 in the same quarter in 2014.
DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of USmarketsDaily.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: